CXCL13 and myeloid sarcoma: In relapsing-remitting MS patients, immunohistochemical and quantitative PCR analyses have detected increased levels of CXCL13 in perivascular spaces and the extracellular matrix in early and highly active MS lesions characterized by high numbers of CD68+ macrophages [15].